>
Located in the Medicine Valley in Zhangjiang Hi-Tech Park in Shanghai, Allist R&D Center boasts a total of 130 researchers and scientists. It now has a complete set of processes for the research and development of new drugs, including drug discovery, preclinical studies, clinical trial application, clinical trials, new drug approval, and post-approval research, etc.
Profile
Shanghai Allist Pharmaceuticals Co., Ltd is co-founded by Mr. Du Jinhao, a renowned entrepreneur, and Dr. Guo Jianhui, tenured scientist of The United States National Institutes of Health (NIH) in. Headquartered in Zhangjiang Hi-Tech Park since its founding in March 2004, Allist has built itself into an innovative pharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines.
Under the development concept of “advancing long life with innovation of science and technology”, it is oriented by the unmet clinical demands in the global pharmaceutical market, with special focus on tumor treatment. Allist seeks to develop first-in-class and best-in-class medicines with uncompromised devotion to produce safe, effective, and inclusive innovative drugs with independent intellectual property rights.
After the A and A+ rounds of financing in 2019, Allist was formally listed on the Sci-Tech Innovation Board (STAR) market via the Shanghai Stock Exchange on December 2, 2020 (Stock code: 688578).
-
-
>
-
-
>
Founded in 2019, Shanghai Allist Marketing Planning Co., Ltd. now has a marketing & sales service network that covers 31 provinces, municipalities, and autonomous regions across the country and a marketing & sales team of over 350 members.
-
>
As an innovative pharmaceutical industrialization base invested by Shanghai Allist Pharmaceuticals, Jiangsu Allist Pharmaceuticals Co.,LTD was founded in Sept 2009 with a registered capital of 240 million RMB.
Science Advisory Broad
Science Advisory Broad (SAB) will provide scientific guidance in pipeline strategy, internal project pitching review, project management, external collaboration, asset license-in, clinical development, and team establishment to Allist Pharmaceuticals, leading Allist to a next level of innovation and development.